Fat Loss
Tirzepatide
Dual GIP/GLP-1 receptor agonist studied in metabolic and weight research.
A$399per vial
Dosage15 mg / 2 mL
TGA-regulated compounding
Third-party purity tested
Cold-chain delivery Australia-wide
Dosing Guidance
Amount2.5–15 mg/week
FrequencyOnce weekly
TitrationStart 2.5 mg, increase every 4 weeks
CycleOngoing with medical supervision
Guidance only. Confirm dosing with your prescribing clinician.
Zenith Precision Delivery System
This peptide is delivered using Zenith's Dual Chamber Precision Pen, allowing automatic peptide reconstitution and accurate dosing without manual mixing.
Pre-filled sterile cartridge
Automatic mixing technology
Precision dosing dial
Travel ready delivery system
Scientific Overview
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.
In clinical research, tirzepatide has demonstrated effects on metabolic parameters and body composition.
This compound represents a newer class of incretin-based therapies.
Mechanistic Context
Tirzepatide activates both GIP and GLP-1 receptors, providing complementary mechanisms for glucose regulation and appetite control.
Research suggests the dual-agonist approach may offer enhanced metabolic benefits compared to single-receptor targeting.
Research Applications
Tirzepatide has been referenced in research relating to:
- Type 2 diabetes management studies
- Obesity treatment research
- Metabolic parameter optimisation
- Comparative efficacy studies
Formulation Context
Tirzepatide is available in approved pharmaceutical formulations for specific indications.
Compounded preparations may differ from registered pharmaceutical products.
Regulatory Status
Information provided is for educational and research awareness purposes only.
Tirzepatide injectable formulations are not listed on the Australian Register of Therapeutic Goods (ARTG).
Topical cosmetic products containing this compound may be available under cosmetic regulatory frameworks.
Always consult a qualified medical professional regarding prescription medicines.
Research Highlights
Formulated based on published research frameworks
Third-party tested for purity and potency
Clinical-grade compounding in TGA-regulated facilities
Related in Fat Loss
This product is a general wellness formulation. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before use. All formulations are compounded in Australian TGA-regulated facilities.
TirzepatideA$399